Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Somatostatin, its receptors and analogs, in lung cancer
Autore:
OByrne, KJ; Schally, AV; Thomas, A; Carney, DN; Steward, WP;
Indirizzi:
Leicester Royal Infirm, Univ Dept Oncol, Leicester LE1 5WW, Leics, EnglandLeicester Royal Infirm Leicester Leics England LE1 5WW WW, Leics, England Tulane Univ, Sch Med, Inst Endocrine Polypeptide & Canc, New Orleans, LA 70112 USA Tulane Univ New Orleans LA USA 70112 de & Canc, New Orleans, LA 70112 USA Vet Affairs Med Ctr, New Orleans, LA USA Vet Affairs Med Ctr New Orleans LA USA airs Med Ctr, New Orleans, LA USA Mater Misericordiae Hosp, Dept Med Oncol, Dublin 7, Ireland Mater Misericordiae Hosp Dublin Ireland 7 t Med Oncol, Dublin 7, Ireland
Titolo Testata:
CHEMOTHERAPY
, volume: 47, anno: 2001, supplemento:, 2
pagine: 78 - 108
SICI:
0009-3157(2001)47:<78:SIRAAI>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN SMALL-CELL; GROWTH-FACTOR-I; GASTRIN-RELEASING-PEPTIDE; BRONCHIAL CARCINOID-TUMOR; NEURON-SPECIFIC ENOLASE; MEDULLARY-THYROID CARCINOMA; ECTOPIC CUSHINGS-SYNDROME; RAT PROSTATE-CANCER; NUDE-MICE; PANCREATIC-CANCER;
Keywords:
somatostatin; receptor; lung cancer; [In-111]pentetreotide; chemotherapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
180
Recensione:
Indirizzi per estratti:
Indirizzo: O'Byrne, KJ Leicester Royal Infirm, Univ Dept Oncol, Leicester LE1 5WW, Leics, England Leicester Royal Infirm Leicester Leics England LE1 5WW ngland
Citazione:
K.J. O'Byrne et al., "Somatostatin, its receptors and analogs, in lung cancer", CHEMOTHERA, 47, 2001, pp. 78-108

Abstract

Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women. Novel approaches to the management of lung cancer are urgently required. Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system. The peptide has numerous functions including inhibition of hormone release, immunomodulation and neurotransmission and is an endogenousinhibitor of cell proliferation and angiogenesis. Somatostatin and its analogs, including octreotide (SMS 201-995), somatuline (BIM 23014) and vapreotide (RC-160), act by binding to specific somatostatin receptors (SSTR) of which there are 5 principal subtypes, SSTR-1-5. Although elevated plasma somatostatin levels may be detected in 14-15% of patients, tumor cell expression appears rare. SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease. [In-111]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease. The potential role of radiolabeled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored. Somatostatin analog therapy results in significant growth inhibition of bothSSTR-positive and SSTR-negative lung tumors in vivo. Recent work indicatesthat these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer. Copyright (C) 2001 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 22:54:38